Mein Warenkorb

CD94

CD94 Molekülinformation

Englischer NameNatural killer cells antigen CD94Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2Target-AliasKLRD1,Killer Cell Lectin Like Receptor D1,Killer Cell Lectin-Like Receptor Subfamily D, Member 1,CD94 Antigen,Killer Cell Lectin-Like Receptor Subfamily D Member 1,NK Cell Lectin-Like Receptor Subfamily D
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameNatural killer cells antigen CD94
Target-AliasKLRD1,Killer Cell Lectin Like Receptor D1,Killer Cell Lectin-Like Receptor Subfamily D, Member 1,CD94 Antigen,Killer Cell Lectin-Like Receptor Subfamily D Member 1,NK Cell Lectin-Like Receptor Subfamily D
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

CD94 Produktliste

  • Attribut

    Protein (5)Antibody (1)

  • Produktbibliothek

    Online (6)

  • Spezies

    Human (2)Rhesus macaque (1)Rat (1)Mouse (2)

  • Etikett

    Mouse IgG Fc Tag (1)His Tag (4)- (1)

  • Marker

    Unconjugated (5)PE Labeled (1)

CD94 Molekülhintergrund

CD94(Natural killer cells antigen CD94) is also known as KLRD1, KP43, NK cell receptor, Killer cell lectin-like receptor subfamily D member 1. CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells.

CD94 Molekülalias

CD94,KLRD1,KP43,NK cell receptor

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
DibotatugDR-01Phase 2 ClinicalDren Bio IncAlopecia Areata; Autoimmune Diseases of the Nervous System; Enteropathy-Associated T-Cell Lymphoma; Leukemia; Leukemia, Large Granular Lymphocytic; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Vitiligo
Details
JV-394JV-394Phase 1 ClinicalThe University Of Texas MD Anderson Cancer CenterNeoplasms
Details

Produktrezensionen

  • Molekülinformation
  • Produktliste
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns